In a sweeping clinical update on This Week in Virology, infectious disease physician Dr. Daniel Griffin delivers a sobering message: the ...
Zacks Investment Research on MSN
Syndax stock falls 16% as Phase II fibrosis study misses primary goal
Syndax Pharmaceuticals SNDX shares fell 15.7% on Tuesday after the company reported that its mid-stage study of axatilimab in ...
A prospective study of 447 food-allergic infants reports a cost-sensitive ensemble model that predicts school-age asthma with ...
Three lines for this morning The Nikkei Stock Average closed yesterday at 67,777.52 yen, down 1,253.40 yen (-1.82%). The main ...
BACKGROUND: Left atrial (LA) stiffening augments the LA V wave, pressurizing the pulmonary artery (PA) out of proportion to ...
Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg ...
The ECG shows sinus rhythm at 84 beats per minute with a left anterior fascicular block. Echocardiography demonstrates mild ...
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des ...
The trial result ends Syndax’s plans to advance the drug further in idiopathic pulmonary fibrosis. The company said the results do not affect ongoing trials of the same drug in other settings.
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...
Introduction Acetazolamide improves sleep apnoea in people living at low altitude and newcomers ascending to high altitude.
Intervertebral disc degeneration (IVDD), driven by progenitor cell loss and oxidative stress, remains a major clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results